Indexed in

License and use

Citations

Cited 2 times in

Altmetrics

Grant support

The authors declare that this study received funding from an Investigator Initiated Sponsored Research grant from Galapagos and by a grant from Asociacion Espanoia de Gastroenterologia. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The Eneida Registry of GETECCU is supported by Janssen, Takeda, Pfizer, Galapagos, AbbVie, Biogen and Lilly.

Analysis of institutional authors

Share

Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

Publicated to:Pharmaceutics. 16 (5): 629- - 2024-05-01 16(5), DOI: 10.3390/pharmaceutics16050629

Authors: Gomez-Labrador, Celia; Ricart, Elena; Iborra, Marisa; Iglesias, Eva; Martin-Arranz, Maria Dolores; de Castro, Luisa; De Francisco, Ruth; Garcia-Alonso, Francisco Javier; Sanahuja, Ana; Gargallo-Puyuelo, Carla J; Mesonero, Francisco; Casanova, Maria Jose; Manosa, Miriam; Rivero, Montserrat; Calvo, Marta; Sierra-Ausin, Monica; Gonzalez-Munoza, Carlos; Calvet, Xavier; Garcia-Lopez, Santiago; Guardiola, Jordi; Garcia, Lara Arias; Marquez-Mosquera, Lucia; Gutierrez, Ana; Zabana, Yamile; Navarro-Llavat, Merce; Poyatos, Rufo Lorente; Piqueras, Marta; Torrealba, Leyanira; Bermejo, Fernando; Ponferrada-Diaz, Angel; Perez-Calle, Jose L; Barreiro-de Acosta, Manuel; Tejido, Coral; Cabriada, Jose Luis; Marin-Jimenez, Ignacio; Roncero, Oscar; Ber, Yolanda; Fernandez-Salazar, Luis; Aler, Blau Camps; Lucendo, Alfredo J; Llao, Jordina; Bujanda, Luis; Villafranca, Carmen Munoz; Domenech, Eugeni; Chaparro, Maria; Gisbert, Javier P

Affiliations

Abstract

Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.

Keywords